How Can We Help?
Skip to content
Wire frame hand with test tube

Our SEKISUI Family

XenoTech was acquired by SEKISUI Medical Co. Ltd in August of 2008 and is now one of the companies comprising SEKISUI Medical Group. SEKISUI Medical Group is one of the four primary business divisions of SEKISUI Chemical Co., LTD. This alignment has allowed us to offer a comprehensive range of services to accelerate drug development, globally. SEKISUI XenoTech is also 1 of 11 subsidiaries that are a part of SEKISUI America Corporation, which represents SEKISUI Chemical in North America and supports each member company by providing reliable resources and assets. As the pioneering Japanese manufacturer in North America, SEKISUI America Corporation has become an unstoppable force of diverse companies striving to achieve satisfaction in Service, Speed, and Superiority while coexisting in harmony with our surroundings. Watch a short video on what these “3S” principles mean to the employees of SEKISUI America Corporation.

Focus on Growth & Advancement in the SEKISUI Medical Group

SEKISUI Medical Group is a global organization incorporating production (including pharmaceuticals, fine chemicals, and enzymes) with diagnostics and drug development. The group is focused on the advancement of new therapeutic research in human, animal and environmental science. To meet the challenges of increasing R&D costs, SEKISUI Medical Group is aggressively building onto its global contract research capabilities by aligning distinguished lineages of proven scientific expertise to accelerate R&D timelines, decrease costs and improve success rates via informed program decision-making. The group combines industry leaders and innovators including, but not limited to, SEKISUI Diagnostics (formerly the diagnostics arm of Genzyme), American Diagnostica Inc (ADI), Veredus Laboratories and, of course, SEKISUI XenoTech and SEKISUI Medical Co. (which integrates multiple former companies).

Partnership with The Drug Development Solutions Center
in Tokai, Japan

SEKISUI Medical Group represents a cohesive aggregation of facilities around the world, including the Drug Development Solutions Center. Initially called the Tokai Research Institute of Daiichi Pure Chemicals Co., Ltd. in 1965, the Drug Development Solutions Center contributes to the advancement and development of academic research through its expertise in radioisotope labeling and in vivo ADME contracted research studies. Over more than 50 years, the Center has grown and expanded to offer a broad range of pharmaceutical development research capabilities, from optimization of lead compounds to post-marketing surveillance of drugs. Through a common relationship to SEKISUI Medical Group, SEKISUI XenoTech and the Drug Development Solutions Center work in tandem to provide drug developers with in vitro and in vivo studies to support nonclinical ADME and DMPK evaluation of novel therapeutics.

The Drug Development Solutions Center is fully accredited by AAALAC International for the ethical use of animals in research and features a campus of almost 150,000 ft of corporate and administrative offices and research laboratories, spanning 8.42 acres in Tokai, Japan. Laboratories include specially outfitted rooms for cell culture, an animal care facility, and a large variety of instrumentation to support both cold (non-radiolabeled) and hot (radiolabeled) compound investigations (including some radioisotope labeling services) for in vivo and in vitro ADME/Tox studies. The Drug Development Solutions Center boasts over 50 years of experience in radiolabeling, 25 years in quantitative whole-body autoradiography (QWBA), and is one of the most trusted in vivo contract research providers in the world.

API Manufacturing

Through another SEKISUI Medical Group subsidiary, we can offer services in active pharmaceutical ingredient (API) manufacturing. 

SEKISUI Medical’s multi-purpose current Good Manufacturing Practice (cGMP) facility is capable of both water-based and organic solvent-based manufacturing to meet any reaction and treatment needs with quality assurance testing and cutting-edge equipment. The Research & Development team can quickly and consistently support the manufacturing of grams up to kilograms of material, spanning pilot-scale up to industrial-scale manufacturing.


BioProduction by SEKISUI is a fermentation focused contract development and manufacturing organization (CDMO) with expertise in enzymes and downstream purification. Their microbial process development capabilities and production experience can assist you with smooth technical transfer and process scale-up.  

Core Competencies

  • E. coli and yeast fermentation
  • Plant tissue extraction
  • Large scale bioprocessing
  • Protein purification
  • Bulk formulation
  • Lyophilization
  • Analytical testing

As part of SEKISUI Diagnostics, BioProduction has been a leader in the manufacturing of high-quality enzymes and specialty biochemicals to the global healthcare market for over 40 years. They have worked with many global partners to supply high-quality materials for a variety of applications, including enzymes and proteins for biotherapeutic manufacture, pharmaceutical production, diagnostic reagents, biosensors, and medical devices.  

005 International Messaging Created with Sketch.

Our Journey

Read more about our history, partnership, growth, and how we work together to provide you with superior solutions to advance your drug’s development

SEKISUI XenoTech Global Headquarters in Kansas City (USA)
018 Microscope Beaker Created with Sketch.

More about working with the team in Tokai

Find details about our partner and how your compound’s development can benefit from the Drug Development Solution Center’s 50 years of in vivo ADME and radiolabeling experience

Tokai laboratory in vivo scientist